Navigation Links
ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
Date:12/4/2007

proceed to Phase I clinical trials by the end of 2007. ThromboGenics has built strong links with the University of Leuven and has exclusive rights to certain therapeutics developed at the University. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland and New York, U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the prospectus.

For further information please contact:

ThromboGenics

Prof. Desire Collen, CEO

Dr. Patrik De Haes, COO

Tel: +32(0)16-34-61-94

Citigate Dewe Rogerson

Valerie Auffray / David Dible / Amber Bielecka

Tel: +44(0)207-638-95-71

valerie.auffray@citigatedr.co.uk


'/>"/>
SOURCE ThromboGenics NV
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
6. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
7. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
8. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
9. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
10. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
11. Arpida Presents Preclinical Data on AR-2474 at ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... YourEncore, an Indianapolis, Indiana-based company that ... and food sciences industries solve complex development, regulatory ... Research Excellence and Safety (ACRES), a Massachusetts-based non-profit ... have partnered to speed innovation in the medical ... to ACRES experts with proven experience, tools, and ...
(Date:4/20/2015)... , April 20, 2015  Ardelyx, Inc. ... focused on cardio-renal, gastrointestinal and metabolic diseases, today ... has joined the Company,s Board of Directors. Dr. ... board level experience, having built and led teams ... regulatory approval and into healthcare systems globally. ...
(Date:4/20/2015)... , April 20, 2015 /CNW/ - Portage Biotech ... Securities Exchange: PBT.U), is pleased to announce that its ... a collaborative research study that showed one of its ... inflammation in brain tissue through inhibition of NFkB signalling ... The permeability of the blood brain barrier ...
(Date:4/18/2015)... Aurigene and its partner ... presenting data at the poster sessions from two ... Annual Meeting (April 18-22 in Philadelphia, ... http://photos.prnewswire.com/prnh/20130418/608115 ) , Aurigene will present ... molecule inhibitors program, which is currently in preclinical ...
Breaking Biology Technology:YourEncore and ACRES Partner to Drive Innovation in Clinical Research 2YourEncore and ACRES Partner to Drive Innovation in Clinical Research 3Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 2Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 3Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 4Portage's CPP Platform Delivers a Peptide Cargo Across Blood Brain Barrier 2Portage's CPP Platform Delivers a Peptide Cargo Across Blood Brain Barrier 3Aurigene to Present its NAMPT and IRAK-4 Inhibitors Programs at AACR 2015 2
... REDWOOD CITY, Calif., Feb. 17, 2011 Codexis, Inc. (Nasdaq: ... U.S. Senator from North Dakota, has been elected to the ... in January 2011 after a 30-year career in the U.S. ... "We are very pleased to welcome Byron Dorgan to our ...
... Healthcare has announced the formation of a Medical Advisory ... Director is Dr. Armand B. Cognetta, distinguished Dermatologist and ... is recognized as a leader and innovator in his ... advocacy in the ongoing development of the Company,s leading ...
... LA JOLLA, Calif., Feb. 17, 2011 CalciMedica, ... inflammatory and autoimmune diseases, today announced that it ... 1 clinical trial of CM2489. CM2489 is a ... studied as a once-daily oral therapeutic for patients ...
Cached Biology Technology:Former Senator Byron Dorgan Elected to Codexis Board 2Sensus Healthcare Announces the Formation of a Medical Advisory Board 2CalciMedica Initiates Phase I Clinical Trial of First CRAC Channel Inhibitor (CCI) for Psoriasis 2
(Date:4/8/2015)... , April 8, 2015  Infinisource, a leading ... services, and Morpho, a leading supplier of biometric ... produce the market,s most advanced biometrically-enabled time clock, ... NXG time clock is setting a bold, new ... data for the small and mid-size employer. When ...
(Date:4/2/2015)... Sweden , April 2, 2015 ... for Q1 2015 attributed to somewhat higher than 125 ... in the year-end report 2014 that revenues for Q1 ... that the company reported for Q4 2014. The operating ... to be negative. The complete interim report will as ...
(Date:3/31/2015)... 31, 2015  Elephant Talk Communications Corp. (NYSE MKT: ... of Software Defined Network Architecture (ET Software DNA® 2.0) ... of approximately $20.4 million for the year ended December ... for the year ended December 31, 2013. ... had completed its multi-year transition away from its legacy ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Revises Revenues for Q1 2015 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... is always a delicate affair. Few researchers, however, ... whose working laboratory aboard the International Space Station ... Earth, traveling at some 17,000 miles per hour. ... University,s Biodesign Institute, is using the ISS platform ...
... PA. -- While most farmers consider viruses and fungi ... wild plants adapt to extreme conditions, according to a ... the hardiness of plants is a key to sustainable ... addition to avoiding possible conflicts over scare resources, said ...
... not translated into proteinare key to physically manipulating DNA in ... Institute. These non-coding RNA-activators (ncRNA-a) have a crucial role in ... say, and have also been connected with diseases, including some ... article of the journal Nature , a team of ...
Cached Biology News:International space station plays host to innovative infectious disease research 2International space station plays host to innovative infectious disease research 3International space station plays host to innovative infectious disease research 4International space station plays host to innovative infectious disease research 5International space station plays host to innovative infectious disease research 6Microbes team up to boost plants' stress tolerance 2'Activating' RNA takes DNA on a loop through time and space 2'Activating' RNA takes DNA on a loop through time and space 3
... This CE-based system provides clear advantages ... (viral load, gene expression), mutation analysis, ... easy-to-use system with microplate connectivity is ... and quality control. The P/ACE ...
The imaging screen-K (Kodak), tritium, is a 20 x 25 cm storage phosphor screen that is used for the quantitation and imaging of 32P, 33P, 35S, 14C, and 3H....
The optional fixed lens, 105 mm, is for use with the VersaDoc imaging systems for imaging small samples at high resolution....
The filter 640DF35 for the Molecular Imager FX is a band pass filter for Texas Red dye....
Biology Products: